SNS-229

N/A

Report date: 2022/10/10 16:53:18
NME

Base Information

Drug NameSNS-229
Drug Alias NameSNS-229
ClassificationSmall molecules
Mechanisms of ActionProtein kinases inhibitorsRAF serine/threonine protein kinase inhibitors3-phosphoinositide-dependent protein kinase 1 inhibitors
TargetsRAF serine/threonine protein kinase3-phosphoinositide-dependent protein kinase 1Protein kinases
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBiogen IdecSunesis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSunesis Pharmaceuticals IncMillennium Pharmaceuticals IncBiogen Idec
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A